The European Medicines Committee’s human medicines committee (CHMP) has backed approval of eight new medicines across a range of indications. Gilead’s remdesivir has been previously recommended for conditional approval for treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen. The drug is the first medicine against
Amgen has announced that the Committee for Medicinal Products for Human Use, has issued a positive opinion recommending a label variation for Neulasta to include the Neulasta Onpro Kit. The Neulasta Onpro Kit combines the efficacy of Neulasta with an innovative on-body injector (OBI) delivery system. Neulasta is indicated in the EU for the reduction
At a meeting last week, the Committee for Medicinal Products for Human Use (CHMP) backed non-new drugs for approval, which included two drugs from AstraZeneca.